Iridex Corporation filings document an ophthalmic medical technology issuer whose disclosures center on laser systems, delivery devices, consumables, and procedure probes for glaucoma and retinal disease applications. Form 8-K reports furnish operating and financial results, preliminary results, Regulation FD investor materials, material agreements, and other material-event disclosures.
Proxy materials describe board matters, executive compensation, equity award valuation adjustments, and pay-versus-performance information. The filing record also includes Nasdaq continued-listing compliance updates, capital-structure context such as stockholders’ equity requirements, exhibits to press releases and presentations, and Inline XBRL cover-page data for formal Exchange Act reporting.
Iridex Corp director reported buying additional company common stock in December 2025. On December 11, 2025, the director purchased 9,080 shares at a weighted average price between $0.9508 and $0.97. On December 12, 2025, the director purchased a further 20,920 shares at a weighted average price between $0.9205 and $0.97, bringing direct beneficial ownership to 280,674 shares of Iridex common stock.
The report also discloses indirect holdings of 69,300 shares held by the director’s spouse and 30,026 shares held through the William M. Moore Trust and the Patricia A. Moore Trust as tenants in common.
IRIDEX Corp's chief financial officer, Romeo R. Dizon, reported acquiring 2,365 shares of common stock on 12/12/2025 at $0.9709 per share. Following this purchase, his direct ownership increased to 92,685 IRIDEX common shares, as disclosed in the Form 4 insider transaction report.
IRIDEX Corporation filed a current report to highlight its participation in the Sidoti Year-End Virtual Investor Conference on December 11, 2025. A live webcast of the presentation is scheduled to begin at 10:45 a.m. Eastern Time and will be available, along with an archived version, in the investors section of the company’s website at www.IRIDEX.com.
The company is also making available a set of presentation materials as Exhibit 99.1. These materials are being furnished, not filed, under Regulation FD, meaning they are shared for information purposes and are not treated as part of the company’s formal financial reporting under Section 18 of the Exchange Act.
IRIDEX CORP reported that its Chief Financial Officer, Romeo R. Dizon, bought additional company stock. On 11/20/2025, he acquired 5,760 shares of common stock in an open market purchase at a price of $0.96 per share. After this transaction, he beneficially owned 88,736 shares of IRIDEX common stock directly.
IRIDEX Corporation (IRIX) reported an insider share purchase by its Chief Financial Officer, Romeo R. Dizon. On 11/19/2025, the CFO bought 1,000 shares of common stock at $0.96 per share in an open-market purchase, bringing his directly owned holdings to 82,976 shares. This activity was reported on a Form 4 filed for a single reporting person.
IRIDEX Corp's Chief Financial Officer, Romeo R. Dizon, reported an open-market purchase of company stock. On 11/18/2025, he bought 2,133 shares of IRIDEX common stock at a price of $0.94 per share, as shown in Table I of the filing. After this transaction, he beneficially owned 81,976 shares of IRIDEX common stock in direct ownership. This report was filed as a Form 4 by a single reporting person, indicating a change in his personal holdings of IRIDEX equity.
IRIDEX Corporation (IRIX) director share purchases disclosed. A company director reported open-market purchases of common stock in two transactions. On 11/14/2025, the director bought 28,157 shares at a weighted average price of $0.9676 per share, in multiple trades between $0.9367 and $0.98. On 11/17/2025, the director bought 21,843 shares at a weighted average price of $0.9654 per share, in multiple trades between $0.95 and $0.98.
After these transactions, the director beneficially owns 250,674 shares directly. In addition, 69,300 shares are held indirectly by the director’s spouse, and 30,026 shares are held indirectly through trusts identified in the footnotes. The filing notes that detailed trade‑by‑trade pricing information is available upon request.
IRIDEX CORP (IRIX) reported an insider stock purchase by its Chief Financial Officer, Romeo R. Dizon. On 11/17/2025, the reporting person bought 3,034 shares of common stock at a price of $0.96 per share and an additional 90 shares at $0.9569 per share in open-market transactions coded as purchases ("P").
Following these transactions, the reporting person beneficially owns 79,843 shares of IRIDEX common stock, held directly. The filing indicates that it is made by one reporting person and confirms the officer status as Chief Financial Officer.
IRIDEX Corporation reported an insider share purchase by its Chief Financial Officer. On 11/14/2025, the CFO acquired 14,769 shares of common stock in an open market purchase coded "P" at a price of $0.88 per share. Following this transaction, the officer beneficially owned 76,719 shares of IRIDEX common stock held directly. This type of report provides transparency about trading activity by senior management in the company’s equity.
IRIDEX (IRIX) reported Q3 2025 results showing total revenues of $12.484M, up from $11.581M a year ago. Gross profit was $4.013M versus $4.323M last year, with a loss from operations of $1.411M improving from $1.870M. Net loss narrowed to $1.573M from $1.933M, as operating expenses declined year over year.
By product, Retina delivered $6.698M and Cyclo G6 $3.537M. The United States contributed $5.588M; EMEA reached $4.033M. A key distributor, Topcon, accounted for 31% of Q3 revenues.
Cash and cash equivalents were $5.573M at quarter‑end (vs. $2.387M at December 28, 2024), aided by $6.0M of Series B convertible preferred stock and a $4.0M convertible note, partially offset by repayment of a prior note. The company recorded a year‑to‑date loss on extinguishment of debt of $1.335M and an inventory write‑down of $0.823M. Deferred revenue ended at $9.416M, including exclusivity fees recognized at $0.4M in Q3.
Total stockholders’ equity increased to $4.681M from $2.097M. Common shares outstanding were 17,189,981 as of November 6, 2025.